Physician profile
Veronica Dean
NPI 1932531027
$2,843.54
in general payments reported to CMS, 2019-2025
32 companies · $21.00 in 2025
The $21.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $725 · 2022: $852 · 2023: $905 · 2024: $341 · 2025: $21.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $309.04 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.88 | 2021-2023 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $257.53 | 2021-2023 | Livalo, Seglentis |
| Pfizer INC. | $227.48 | 2021-2024 | |
| Abbott Laboratories | $191.87 | 2021-2023 | Freestyle Libre 3, Eterna |
| Abbvie INC. | $181.52 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.62 | 2021-2024 | |
| Astellas Pharma US INC | $135.68 | 2021-2023 | Veozah |
| Novo Nordisk INC | $128.00 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $92.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $83.85 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.65 | 2022-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $78.02 | 2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $76.11 | 2021-2023 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $68.56 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.84 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $50.48 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.85 | 2023-2024 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $44.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.29 | 2022-2023 | Keveyis |
| Esperion Therapeutics, INC. | $32.91 | 2021-2024 | Nexletol |
| Eisai INC. | $30.15 | 2021 | |
| Dynavax Technologies Corporation | $30.02 | 2023 | Heplisav-B |
| Amarin Pharma, INC. | $28.00 | 2021 | |
| Exact Sciences Corporation | $27.49 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $25.48 | 2021 | |
| Medtronic, INC. | $22.29 | 2023 | Intellis Adaptivestim |
| Aimmune Therapeutics, INC. | $17.68 | 2024 | |
| Sumitomo Pharma America, INC. | $16.78 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $16.41 | 2022 | |
| Genentech USA, INC. | $14.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.